The Drug Delivery Devices Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Drug Delivery Device Market is estimated to be USD 1,179.2 billion in 2016 and predicted to rise to USD 1669.4 Billion by 2021with a CAGR of 7.2%. The market is segmented by Route of administration (Oral Drug Delivery, Pulmonary Drug Delivery, Inject able Drug Delivery , Ocular Drug Delivery , Nasal Drug Delivery, Topical Drug Delivery , Implantable Drug Delivery , Tran mucosal Drug Delivery), by Facility of use (Hospitals, Ambulatory Surgical Centers, Home Care settings, Diagnostic Centers, Other). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
The drug delivery technology market is expected to development in the coming years, because of the new innovations and technical advancements. The drivers for Drug delivery market are Increase in prevalence of chronic diseases, increase in the advancement of technology, rise in individual therapy, Increase in the awareness about drug metabolism among people and need for the control on drug release. Few restraints which account for the fall of the market are fear amoung individuals regarding injuries and infections during utlisation, rise in the cost of development and strick regulatory framework.
Some of the key players in the market are, Bend Research, Endocyte, MicroCHIPS Inc, Pearl Therapeutics Inc, Presage Bioscience, UCB Group, Genentech Inc, Polymer Factory, Alkermes Inc, BIND Biosciences Inc, QLT Inc.
Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-drug-delivery-devices-market-2346/” and checkout our recent reports in the Medical Devices category at “http://www.marketdataforecast.com/research-reports/healthcare/medical-devices-2/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.